{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:42:32Z","timestamp":1780393352860,"version":"3.54.1"},"reference-count":64,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2015,12,19]],"date-time":"2015-12-19T00:00:00Z","timestamp":1450483200000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:p>Multiple myeloma is a neoplastic plasma cell disorder that is characterized by clonal proliferation of plasma cells in the bone marrow, monoclonal protein in the blood and\/or urine, and associated organ dysfunction and biomarkers. There have been multiple recent advances in the relapsed and refractory setting. Major steps forward include the introduction of proteasome inhibitors (bortezomib and carfilzomib) and immunomodulatory drugs (thalidomide, lenalidomide, and pomalidomide) in various combinations. These drugs have changed the management of multiple myeloma and have extended overall survival in the past decade. Established curative therapy is not yet available for patients diagnosed with multiple myeloma, supporting the development of new treatment targets. Histone deacetylase inhibitors have multiple proposed mechanisms of action in the treatment of multiple myeloma. Both vorinostat and panobinostat have demonstrated some activity against multiple myeloma, and due to the benefits reported with panobinostat, the U.S. Food and Drug Administration has recently approved the drug for the treatment of relapsed and refractory multiple myeloma. In this article, we describe the pharmacology, efficacy, and toxicity profile of vorinostat and panobinostat and their possible place in therapy.<\/jats:p>","DOI":"10.1002\/phar.1671","type":"journal-article","created":{"date-parts":[[2015,12,19]],"date-time":"2015-12-19T02:57:39Z","timestamp":1450493859000},"page":"1173-1188","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat"],"prefix":"10.1002","volume":"35","author":[{"given":"Salma","family":"Afifi","sequence":"first","affiliation":[{"name":"Department of Pharmacy Memorial Sloan Kettering Cancer Center New York New York"},{"name":"Department of Medicine Myeloma Service Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Michael","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahshid","family":"Azimi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mabel","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoletta","family":"Lendvai","sequence":"additional","affiliation":[{"name":"Department of Medicine Myeloma Service Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[{"name":"Department of Medicine Myeloma Service Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,12,19]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21254"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.291"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.196"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra072067"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07976.x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/38664"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-013-1290-3"},{"issue":"10","key":"e_1_2_8_10_1","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1158\/1541-7786.MCR-07-0324","article-title":"Histone deacetylase inhibitors: overview and perspectives","volume":"5","author":"Dokumanovic M","year":"2007","journal-title":"Mol Cancer Res"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.03.016"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-010-9589-x"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2012.01.006"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4186"},{"issue":"1","key":"e_1_2_8_15_1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1182\/blood.V90.1.279.279_279_289","article-title":"Interleukin\u20106 overcomes p21WAF1 upregulation and GI growth arrest induced by dexamethasone and interferon\u2010\u03b3 in multiple myeloma cells","volume":"90","author":"Urashima M","year":"1997","journal-title":"Blood"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3514"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4400758"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1593\/neo.04655"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0561"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-016055"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1334037100"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3531"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0433"},{"key":"e_1_2_8_24_1","unstructured":"Patheon Inc.Zolinza (vorinostat) package insert.Mississauga Ontario Canada;2013."},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2220-z"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e32834a8639"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1802"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2536759100"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701817258"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.1"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2850"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.07.007"},{"key":"e_1_2_8_33_1","unstructured":"VoorheesPM GasparettoC OsmanK et\u00a0al.Results of a phase I study of vorinostat in combination with pegylated liposomal doxorubicin and bortezomib in patients with relapsed\/refractory multiple myeloma. [Abstract #1955]. Presented at the 53rd ASH Annual Meeting and Exposition. San Diego CA December 10\u201013 2011."},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13517"},{"key":"e_1_2_8_35_1","doi-asserted-by":"crossref","unstructured":"SiegelDS DimopoulosMA YonSS et\u00a0al.Vantage 095: vorinostat in combination with bortezomib in salvage multiple myeloma patients: final study results of a global phase 2b trial. [Abstract #480]. Presented at the 53rd ASH Annual Meeting and Exposition. San Diego CA December 10\u201013 2011.","DOI":"10.1182\/blood.V118.21.480.480"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70398-X"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1214"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S30773"},{"key":"e_1_2_8_39_1","unstructured":"Novartis Pharmaceuticals Corporation.Farydak (panobinostat). East Hanover New Jersey; 07936."},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-012-1940-9"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-011-1693-x"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-011-1758-x"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0511"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-013-9930-2"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.09.36"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.38"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.661175"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.7068"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-481325"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70440-1"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.119735"},{"key":"e_1_2_8_52_1","doi-asserted-by":"crossref","first-page":"8030","DOI":"10.1200\/jco.2010.28.15_suppl.8030","article-title":"Phase Ib study of oral panobinostat (LBH589) plus lenalidomide plus dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma","volume":"25","author":"Mateos M","year":"2010","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_53_1","unstructured":"ChariA ChoH ParekhS et\u00a0al.A phase II single\u2010center open\u2010label study of oral panobinostat in combination with lenalidomide and weekly dexamethasone in patients with multiple myeloma. [Abstract #3486]. Presented at the 56th ASH Annual Meeting and Exposition.San Francisco CA December 6\u20109 2014."},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.664844"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1910-2"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-318055"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25584"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-339879"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1786"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2008.01102.x"},{"key":"e_1_2_8_61_1","unstructured":"NCT00431340.A Phase II study of belinostat in combination with bortezomib in patients with relapsed refractory multiple myeloma. Available at:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00431340[accessed 08.18.15]."},{"issue":"1","key":"e_1_2_8_62_1","first-page":"00","article-title":"A phase II study of PXD101 in advanced multiple myeloma","volume":"108","author":"Sullivan D","year":"2006","journal-title":"Blood"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-387365"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.29"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25660"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1671","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1671","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1671","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:41:15Z","timestamp":1761064875000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":64,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["10.1002\/phar.1671"],"URL":"https:\/\/doi.org\/10.1002\/phar.1671","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"2015-12-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}